To include your compound in the COVID-19 Resource Center, submit it here.

IMI launching project for adaptive Alzheimer's trial

During the G8 Dementia Summit, the EU's Innovative Medicines Initiative (IMI) unveiled a EUR 53 million ($72.7 million) project (EPOC-AD) aimed at developing an adaptive proof-of-concept

Read the full 266 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE